zhongbiao nie

Mr. zhongbiao nie


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2022 in Journal of Pain Research
Verified
Journal Article
Open access
PDF file
ZNzhongbiao nie
zhongbiao nie
XCXianmei Cui
Xianmei Cui
RZRan Zhang
Ran Zhang
ZLZhihong Li
Zhihong Li
BLBin Lu
Bin Lu
PZPing Zhuang
Ping Zhuang
Purpose: To investigate the effectiveness of sufentanil patient-controlled intravenous analgesia pump (PCIA) and background infusion in patients of post-cesarean analgesia. Patients and Methods: This trial compared two groups of women undergoing cesarean section and receiving PCIA: no background infusion group (n=30), 6-min lockout time, and background infusion group (n=30), 2 mL/h infusion, 10-min lockout time. Both groups with 2 μg/kg sufentanil was diluted to 100 mL with normal saline. VAS scores at rest at 36 h was the primary endpoint. The secondary endpoints were the VAS scores at rest at 6, 12, and 24 h, the total amount of sufentanil consumed, the Ramsay sedation score (RSS) assessed at the same time points, postpartum bleeding within 24 h, the injection/attempt (I/A) ratio, BP and HR, PONV, side effects of sufentanil. Results: Compared with the no background infusion group, the background infusion group showed lower VAS pain scores at 6, 12, and 24 h (P< 0.01), but no differences at 36 h (95% CI = − 0.5– 0.8. P> 0.05). Attempts, injections, and total sufentanil consumption were significantly different between the two groups (P< 0.001), but without difference in I/A. Bleeding was less in the background infusion group at 1 h (P=0.03). The minimal respiration rates were not significantly different between groups. Conclusion: Background infusion increased the total consumption of sufentanil within 36 h after cesarean section. Although it did not reduce uterine contraction pain and wound pain at 36 h, it significantly reduced the pain at 6, 12, and 24 h after cesarean section. It improved patient satisfaction and reduced the amount of bleeding after 1 h. Importantly, it did not increase the incidence of hypertension, PONV and respiratory depression.

4 November 2024 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
RZRan Zhang
Ran Zhang
YLYanyan Li
Yanyan Li
ZNzhongbiao nie
zhongbiao nie
This study aimed to present an overview of the current status of research and important discoveries about immunotherapy for glomerulonephritis in general using bibliometric analysis. We collected the literature on immunotherapy for glomerulonephritis from the Web of Science (WOS) database for the last 10 years (2014–2024), and we assessed the mapping of knowledge using Citespace. The findings demonstrated that there were 258 articles concerning the immunotherapy for glomerulonephritis, with a faster growth after 2018. The USA, Charite Universitatsmedizin Berlin, and Anders, Hans-Joachim are the nation, organization, and writer with the highest number of publications. The most often cited reference is Rovin BH (2021) as well (5). The best partnerships are formed by prestigious universities and developed countries for glomerulonephritis research on immunotherapy. Three research hotspots in this area are rituximab, adjuvant, and antibody production erythematosus, respectively.

22 December 2023 in Medicine
Verified
Journal Article
Open access
ZZZiwei Master Zhao
Ziwei Master Zhao
YLYanyan Li
Yanyan Li
PWPeili Wang
Peili Wang
RZRan Master Zhang
Ran Master Zhang
ZNzhongbiao nie
zhongbiao nie
To determine current research objectives and predict future trends in studies on the relationship between genetics and major depressive disorder (MDD). We collected the publications in the last 20 years (2003–2023) related to genetics and MDD in the Web of Science database, and applied Citespace to assess the knowledge mapping. The number of manuscripts about genetics and MDD totaled 9200, with a faster increase after 2013. The country, institution, and author with the most publications are the USA, the University of London, and Serretti, Alessandro. BIOL PSYCHIAT published the most articles in this field. In addition, the most co-cited reference is Sullivan PF (2000) (673). Genetic and MDD research, including the hippocampus, and HPA axis may become the focus of research in the future. Based on a 20-year scientometric investigation, we know the USA, China, and Germany have emerged as the important research forces in this discipline. The strongest collaborations between developed countries and renowned institutions are beneficial to the advancement of genetic and MDD research. Serotonin is the strongest citation bursts keyword.

2 December 2022 in Medicine
Verified
Journal Article
Open access
RZRan Master Zhang
Ran Master Zhang
YLYan-Yan Li
Yan-Yan Li
ZNzhongbiao nie
zhongbiao nie
XZXue-Qin Master Zhang
Xue-Qin Master Zhang
YMYanmiao Ma
Yanmiao Ma
YWYong-Hui Wang
Yong-Hui Wang
This study aims to demonstrate current research priorities and predict future trends in the link between kidney disease and gut microbiota by means of scientometric analysis. We collected nearly 20 years (2001–2020) of publications related to kidney disease and gut microbiota in the Web of Science database. CiteSpace was used to evaluate the knowledge mapping. There are 965 manuscripts about kidney disease and gut microbiota in total, and faster growth after 2016. The country, institution, and author who posted the most are the USA, Univ Calif Irvine, and DENISE MAFRA, respectively. The frequencies are 109, 16, and 17. The most important of them are FRANCE (0.23), Fed Univ Parana UFPR (0.13), and VAZIRI ND (1.14), owing to their highest centrality. In addition, the cited documents that have contributed the most to the co-citations are Wong J (2014); the most key cited reference is Rossi M (2016); the most commonly used keywords are chronic kidney disease, gut microbiota and indoxyl sulfate. Through scientometric analysis of the past 20 years, we obtained the knowledge map of this information, which has important guiding significance for accurately and quickly locating trends in this field.

1 January 2024 in Journal of Clinical Pharmacy and Therapeutics
Verified
Journal Article
Open access
PDF file
JZJun Zhang
Jun Zhang
QGQin Guo
Qin Guo
RZRan Zhang
Ran Zhang
MWMenghui Wei
Menghui Wei
ZNzhongbiao nie
zhongbiao nie
Objective. To identify gender differences in the adverse events (AEs) of ketamine, reduce the AEs among patients, and contribute to the advancement of personalized medicine. Methods. A normalized dataset from 2004 Q1 to the 2022 Q4 in the US Food and Drug Administration Adverse Event Reporting System (FAERS) was analysed. The reporting odds ratio (ROR), proportional reporting ratio (PRR), and P value were used to detect the risk signals from the data in the FAERS database and quantify the presence and extent of gender differences in ketamine AEs. Results. Totally, 5,477 ketamine (female/male (2507/1795)) AE reports were analysed, and sedation (ROR 1.30 (1.07, 1.58)), suicidal ideation (ROR 1.30 (1.03, 1.64)), nausea (ROR 1.37 (1.05, 1.78)), depression (ROR 1.22 (1.13, 1.61)), dizziness (ROR 2.25 (1.78, 2.90)), anxiety (ROR 1.48 (1.09, 1.99)), and other adverse events were found to be significantly more frequent in male patients than in female patients. Conclusion. Using FAERS, we identified gender as factors associated with ketamine‐related AEs. With the limitations inherent to this open data source, our data need prospective validation but elucidate potential factors for a personalized side effect profiling.

25 September 2024 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
RLRuijuan Li
Ruijuan Li
RZRan Zhang
Ran Zhang
YJYuheng Jia
Yuheng Jia
ZNzhongbiao nie
zhongbiao nie
Using bibliometric analysis, this study attempted to provide an overview of the current state of research and key findings regarding the immunotherapy for vasculitis in general. We gathered the literature from the Web of Science (WOS) database covering the last 20 years (2004-2024) pertaining to the immunotherapy for vasculitis, and we used Citespace to evaluate the mapping of knowledge. The findings demonstrated that there were 572 articles concerning the immunotherapy for vasculitis, with a faster growth after 2018. The USA, Assistance Publique Hopitaux Paris, and Cornelia M are the nation, organization, and writer with the highest number of publications. Daxini A (2018) is the most frequently mentioned reference as well (26). Prominent universities and developed nations form the finest alliances for research on immunotherapy for vasculitis researches. Immune checkpoint inhibitors, Wegener's granulomatosis, and systemic lupus erythematosus are Three research hotspots in this field.